福萊新材(605488.SH):煙台富利一期項目第一條年產約5萬噸BOPP薄膜生產線已投產
格隆匯7月19日丨有投資者向福萊新材(605488.SH)提問:請問富利新材投資16億元,總產能23萬噸功能膜目前進展如何?一期投產後可以達到多少產值?
福萊新材回覆:煙台富利一期項目第一條年產約5萬噸BOPP薄膜生產線已投產,第二條BOPP產線在已有的第一條產線的經驗基礎上正在積極建設中,預計2024年年初投產,一期項目整體投產後預計可達10億元產值;二期項目的兩條年產4.6萬噸PETG 熱收縮膜生產線正在積極建設中,預計2024年四季度投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.